What attention deficit hyperactivity disorder is
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition characterised by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with daily functioning. It is typically identified in childhood and often continues into adulthood. Standard treatment in the UK includes psychoeducation, behavioural strategies, and medication — most commonly stimulants such as methylphenidate and lisdexamfetamine, and non-stimulants such as atomoxetine.
Cannabis research on Attention deficit hyperactivity disorder
One randomised controlled trial of a cannabinoid preparation for ADHD has been published. A 2017 pilot trial tested nabiximols, a cannabis-extract oromucosal spray containing THC and CBD in roughly equal proportions, in 30 adults with ADHD. On the primary outcome — a computerised test of cognitive performance and activity level — the intention-to-treat analysis showed no statistically significant difference between groups. The active group produced a nominally significant improvement in hyperactivity/impulsivity and a cognitive measure of inhibition, with trends toward improvement in inattention and emotional lability. These did not remain significant after correction for multiple comparisons. The authors described the findings as preliminary evidence for the self-medication hypothesis — the idea that some adults with ADHD may use cannabis because they subjectively experience symptom reduction — rather than evidence of treatment efficacy.
No further randomised controlled trials of a cannabis product for ADHD have been published since 2017.
Human observational data are sparse. Some survey studies, not reviewed in detail here, report that adults with ADHD self-identify cannabis use as helpful for restlessness, sleep, or emotional regulation. These reports are uncontrolled and subject to recall and selection bias. A 2026 preprint study linked ADHD to altered neural response inhibition and cannabinoid receptor 1 function, suggesting a neurobiological overlap between the endocannabinoid system and attention circuitry, but this work was observational and does not test a treatment.
In cell and animal research, cannabinoids modulate dopamine release in prefrontal circuits relevant to attention and impulse control. Rodent studies have shown that cannabinoid agonists can affect hyperactivity and attention measures, but these findings are preclinical and the direction of effect depends on dose, developmental stage, and the specific model used. Preclinical data do not translate directly to treatment predictions for people.
Compounds studied for Attention deficit hyperactivity disorder
THC is the only cannabinoid tested in a published randomised controlled trial for ADHD. In that 30-person pilot trial, THC was administered as part of a THC/CBD combination spray. The trial did not demonstrate efficacy on the primary endpoint. The relationship between THC and dopamine release in prefrontal circuits is a subject of ongoing preclinical research, but no human trial has isolated THC alone for ADHD.
CBD was included as a component in the single published ADHD randomised trial. No human trial has tested CBD alone for ADHD core symptoms. Preclinical research has examined CBD’s effects on impulsivity in animal models, but these have not been tested in controlled human ADHD studies.
Pinene is a terpene that has been associated with alertness in preclinical and small human laboratory studies on olfactory exposure. There is no controlled research testing pinene as an intervention for ADHD.
Limonene has been studied in preclinical models for mood-elevating effects. There is no human ADHD-specific research on limonene.
Terpinolene is a mildly sedating terpene found in some cannabis varieties. No human studies have examined terpinolene for ADHD or its symptoms.
Limits of the evidence for Attention deficit hyperactivity disorder
The published controlled evidence for cannabinoids and ADHD consists of one pilot randomised trial of 30 adults. That single trial did not meet its primary endpoint, and the secondary outcomes that appeared nominally significant did not survive statistical correction.
No randomised controlled trial has tested a cannabinoid preparation against an established ADHD medication. No trial has followed ADHD patients on cannabinoids for longer than a few weeks. No trial has been conducted in children or adolescents with ADHD — the population in which the condition is most commonly diagnosed and treated.
The preclinical literature on dopamine and endocannabinoid interaction provides mechanistic suggestion but not clinical evidence. The self-medication hypothesis, while plausible as a description of behaviour, is not a demonstration that cannabis products produce reliable symptom reduction in controlled conditions.
There are no controlled data on the safety of regular cannabinoid use in people with ADHD, particularly in younger populations where brain development is ongoing. The single trial recorded one serious adverse event (muscular seizures/spasms) in the active group.
Sources
1. Cooper RE, et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. European Neuropsychopharmacology. 2017. PMID: 28576350. Study record DOI: 10.1016/j.euroneuro.2017.05.005. 2. ADHD Symptoms and Cannabis Use: The Role of Cannabinoid Receptor 1 and Neural Response Inhibition. medRxiv preprint. 2026. PMID: 42428127. Study record 3. Cannabinoids and ADHD: a New Frontier in Neuropharmacology? Current Neuropharmacology. 2025. PMID: 41165995. Study record
